Do spironolactone, bupropion (Wellbutrin), and mirtazapine cause hepatic toxicity or elevate liver enzymes?

Yes, all three medications can cause liver issues, though the risk and severity vary significantly among them.

Bupropion (Wellbutrin)

Bupropion carries documented hepatotoxicity risk affecting 0.1-1% of treated patients, presenting with either hepatocellular or cholestatic patterns of liver injury 1. The mechanism is predominantly immune-mediated, typically occurring within 1-6 weeks of treatment initiation 1. Case reports demonstrate dramatic elevations in transaminases (up to 68-fold normal limits) and bilirubin (up to 28 mg/dL), with cholestatic hepatitis patterns 2.

The FDA drug label confirms extensive hepatic metabolism via cytochrome P450 enzymes, with particular caution advised in patients with hepatic impairment 3. In severe hepatic cirrhosis, bupropion Cmax and AUC increase substantially (approximately 70% and 3-fold respectively), with prolonged half-life (29 vs 19 hours) 3.

Key monitoring points:

• Hepatotoxicity typically manifests within the first 6 weeks of treatment
• Symptoms may include asthenia, nausea, jaundice, or may be asymptomatic with only biochemical abnormalities
• Liver enzymes normalize within 2 months of discontinuation 2
• Rechallenge is contraindicated once hepatotoxicity is established

Mirtazapine (Remeron)

Mirtazapine can cause hepatotoxicity including steatosis and elevated liver enzymes, though this is less commonly reported than with bupropion 4, 5. Recent evidence demonstrates that mirtazapine promotes hepatic steatosis through the TLR4/MyD88/NF-κB inflammatory signaling pathway 6. Clinical presentations include:

• Asymptomatic transaminase elevations 4
• Painless jaundice with steatosis on imaging 5
• Dose-dependent lipid accumulation in hepatocytes 6

A 2024 study identified mirtazapine use as an independent risk factor for NAFLD development in patients with depression, with risk increasing with longer duration of use 6. The guideline reference notes mirtazapine should be monitored for hepatotoxicity, though it's generally well-tolerated 7.

Clinical considerations:

• Hepatotoxicity can occur even at low doses used for insomnia 4
• Liver function typically normalizes rapidly after discontinuation 4, 5
• Consider baseline and periodic liver enzyme monitoring, especially with prolonged use
• Age and duration of treatment increase NAFLD risk 6

Spironolactone

Spironolactone has the lowest hepatotoxicity risk of the three medications, with very rare cases of mixed cholestatic/hepatocellular toxicity reported 8. The FDA label documents "a very few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality" 8. One case report describes hepatitis occurring 6 weeks after initiation, which resolved upon discontinuation 9.

Guidelines recommend using spironolactone with caution in hepatic impairment and avoiding it in severe hepatic impairment (Child-Pugh score >9) 10. The drug should be avoided in patients with underlying liver disease or those taking other hepatotoxic medications 11.

Practical approach:

• Baseline liver function tests are reasonable but not mandated
• Monitor for symptoms: pruritus, jaundice, right upper quadrant pain
• Discontinue immediately if hepatitis suspected
• Generally safe in patients with normal baseline hepatic function

Common Pitfalls to Avoid

1. Don't dismiss mild transaminase elevations - Early recognition prevents progression to severe hepatotoxicity
2. Don't rechallenge with bupropion after documented hepatotoxicity - cross-reactivity with other serotonergic agents may occur 12
3. Don't assume low-dose therapy is safe - mirtazapine hepatotoxicity occurs even at doses used for insomnia 4
4. Don't combine multiple hepatotoxic agents without enhanced monitoring - the guideline explicitly warns against this 11

In summary: Bupropion poses the highest and most clinically significant hepatotoxicity risk (0.1-1% incidence), mirtazapine carries moderate risk particularly with chronic use, and spironolactone has very rare hepatotoxicity. Baseline liver function testing is prudent for all three, with closer monitoring for bupropion and mirtazapine, especially in the first 2-3 months of therapy.